CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
research
Chemotherapy-Response Monitoring of Breast Cancer Patients Using Quantitative Ultrasound-Based Intra-Tumour Heterogeneities
Authors
A Ahmed
A Guimond
+69 more
A Sadeghi-Naini
A Sadeghi-Naini
A Sadeghi-Naini
A Sadeghi-Naini
A Sadeghi-Naini
A Sadeghi-Naini
A Sadeghi-Naini
B Banihashemi
B Fisher
B Ganeshan
BS Garra
BS Pio
BT Hennessy
C-P Chou
D Sethi
DA Mankoff
EJ Feleppa
EJ Feleppa
F Tixier
FJ Esteva
FL Lizzi
FT D’Astous
G Berger
G Minckwitz von
GJ Czarnota
GJ Czarnota
GN Hortobagyi
H Haibo
H Tadayyon
H Tadayyon
H Tadayyon
HC Kim
HM Kuerer
II Wistuba
J Czernin
JB Nikas
JPB O’Connor
K Brindle
K Sikora
K Suzuki
KA Wear
KM Brindle
KN Ogston
L Sannachi
LX Yao
M Dowsett
M Vaidya
MF Insana
ML Oelze
ML Oelze
N Duric
O Falou
O Falou
QH Huang
R Tiling
RM Haralick
RM Vlad
RM Vlad
SH Giordano
SH Giordano
SJ Cleator
SM Scholl
T Cover
TJ Larkin
U McDermott
V Goh
V Guarneri
X Li
Y Labyed
Publication date
1 September 2017
Publisher
'Springer Science and Business Media LLC'
Doi
Cite
Abstract
© 2017 The Author(s). Anti-cancer therapies including chemotherapy aim to induce tumour cell death. Cell death introduces alterations in cell morphology and tissue micro-structures that cause measurable changes in tissue echogenicity. This study investigated the effectiveness of quantitative ultrasound (QUS) parametric imaging to characterize intra-tumour heterogeneity and monitor the pathological response of breast cancer to chemotherapy in a large cohort of patients (n = 100). Results demonstrated that QUS imaging can non-invasively monitor pathological response and outcome of breast cancer patients to chemotherapy early following treatment initiation. Specifically, QUS biomarkers quantifying spatial heterogeneities in size, concentration and spacing of acoustic scatterers could predict treatment responses of patients with cross-validated accuracies of 82 ± 0.7%, 86 ± 0.7% and 85 ± 0.9% and areas under the receiver operating characteristic (ROC) curve of 0.75 ± 0.1, 0.80 ± 0.1 and 0.89 ± 0.1 at 1, 4 and 8 weeks after the start of treatment, respectively. The patients classified as responders and non-responders using QUS biomarkers demonstrated significantly different survivals, in good agreement with clinical and pathological endpoints. The results form a basis for using early predictive information on survival-linked patient response to facilitate adapting standard anti-cancer treatments on an individual patient basis
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Crossref
See this paper in CORE
Go to the repository landing page
Download from data provider
info:doi/10.1038%2Fs41598-017-...
Last time updated on 11/12/2019
Sheffield Hallam University Research Archive
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:shura.shu.ac.uk:25709
Last time updated on 05/02/2020